For much of the past decade, drug shortages in the United States were treated as episodic disruptions. In 2024, that framing ...

This investment coincides with China’s burgeoning presence in the pharmaceutical industry, driven by an uptick in innovative medicines R&D.

Laine Mello, director of Marketing at Ecolab for its bioprocessing business, shares her insights on the digital ...

TopGum Industries signed a binding letter of intent to acquire U.S.-based operations manufacturing pharmaceutical products and dietary supplements in gummy dosage form, marking TopGum’s entry into ...

Operating under the FDA's 503B pathway, the Apex facility will prioritize the production of generic shortage-listed ...

TopGum Industries Ltd. (TASE: TPGM), the leading company in the dietary supplements gummy dosage-form market, announced today that it has signed a Binding Letter of Intent (LOI) to acquire U.S.

A CDMO championing a commitment to patients may sound like lip service or branding, but truly patient-centric CDMOs offer ...

The U.S. will impose a 100% tariff on "all any branded or patented Pharmaceutical Product" entering the country from Oct. 1. The measure will not apply to companies building drug manufacturing plants ...

When it came to deciding where to build a new manufacturing facility for its ambitious metabolic drug program, Roche undertook a thorough search that included 12 high-tech clusters in the U.S. and ...